Phosphoglycerate mutase 1 （PGAM1） is upregulated in many cancer types and involved in cell proliferation, migration, invasion, and apoptosis. However, the relationship between PGAM 1 and prostate cancer is poorly un...Phosphoglycerate mutase 1 （PGAM1） is upregulated in many cancer types and involved in cell proliferation, migration, invasion, and apoptosis. However, the relationship between PGAM 1 and prostate cancer is poorly understood. The present study investigated the changes in PGAM1 expression in prostate cancer tissues compared with normal prostate tissues and examined the cellular function of PGAM1 and its relationship with clinicopathological variables. Immunohistochemistry and Western blotting revealed that PGAM 1 expression was upregulated in prostate cancer tissues and cell lines. PGAM 1 expression was associated with Gleason score （P = 0.01） and T-stage （P = 0.009）. Knockdown of PGAM 1 by siRNA in PC-3 and 22Rv I prostate cancer cell lines inhibited cell proliferation, migration, and invasion and enhanced cancer cell apoptosis. In a nude mouse xenograft model, PGAM1 knockdown markedly suppressed tumor growth. Deletion of PGAM1 resulted in decreased expression of Bcl-2, enhanced expression of Bax, caspases-3 and inhibition of MMP-2 and MMP-9 expression. Our results indicate that PGAM1 may play an important role in prostate cancer progression and aggressiveness, and that it might be a valuable marker of poor prognosis and a potential therapeutic target for prostate cancer.展开更多
基金This study was supported by three Science and Technology planning Projects of Guangdong Province （No. 2013B051000050, No. 2014A020212538, and No. 2016A020215175）, the Natural Science Foundation of Guangdong Province （No. 2016A030313583）, the Medical Scientific Research Foundation of Guangdong Province （No. A2016555）, the Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University （No. 2015J005）, and the Science and Technology planning Project of Guangzhou （No. 201704020070 ）.
文摘Phosphoglycerate mutase 1 （PGAM1） is upregulated in many cancer types and involved in cell proliferation, migration, invasion, and apoptosis. However, the relationship between PGAM 1 and prostate cancer is poorly understood. The present study investigated the changes in PGAM1 expression in prostate cancer tissues compared with normal prostate tissues and examined the cellular function of PGAM1 and its relationship with clinicopathological variables. Immunohistochemistry and Western blotting revealed that PGAM 1 expression was upregulated in prostate cancer tissues and cell lines. PGAM 1 expression was associated with Gleason score （P = 0.01） and T-stage （P = 0.009）. Knockdown of PGAM 1 by siRNA in PC-3 and 22Rv I prostate cancer cell lines inhibited cell proliferation, migration, and invasion and enhanced cancer cell apoptosis. In a nude mouse xenograft model, PGAM1 knockdown markedly suppressed tumor growth. Deletion of PGAM1 resulted in decreased expression of Bcl-2, enhanced expression of Bax, caspases-3 and inhibition of MMP-2 and MMP-9 expression. Our results indicate that PGAM1 may play an important role in prostate cancer progression and aggressiveness, and that it might be a valuable marker of poor prognosis and a potential therapeutic target for prostate cancer.
